Surgery Versus Radiation Therapy

By Paul T. Finger, MD

Information to help you make the best decision!

Surgical removal of the iris and ciliary body (called iridectomy, iridocyclectomy or eye wall resection) has been associated with risks of tumor leakage, intraocular hemorrhage, lens dislocation and retinal detachment.

Iris surgery also causes enlarged pupils and therefore lifelong problems with glare.

So, over 30-years ago I wondered why patients have to lose their iris and risk intraocular complications to have their tumor destroyed. My experience with plaque radiation for anterior segment tumors (melanoma, carcinoma), showed that plaque radiation offers preservation of the iris and its function.

I have published reports have demonstrated local control rates of over 97% with almost no risk for radiation damage to the macula or optic nerve.

“In our recent report of patients treated with plaque radiation therapy for iris melanoma we noted that most patients developed cataract, but all were able to have cataract surgery to correct their vision.

“I believe there is little reason to perform surgical excision to treat iris and ciliary body melanomas.” - Dr. Finger
High-frequency ultrasound imaging (UBM) has revolutionized the practice of ophthalmology and ophthalmic oncology. It allows us to visualize the deep margins and measure eyelid, conjunctival, iris, iridociliary and anterior uveal tumors.

As seen below, ultrasound allows a view inside a cystic or solid tumor. These images of the iris and ciliary body allow us to “see” in previously obscure parts of the eye.

Dr. Finger and associates originally described the use of UBM for measurement of anterior melanomas before and after plaque radiation treatment.

We were the first to describe its use to find hidden retinoblastoma tumors behind the iris and lens and pioneered its use to determine if conjunctival squamous carcinoma that have invaded the eye.

“All iris tumors should have an initial evaluation that includes high frequency ultrasound imaging (UBM) and digital photographic imaging.”

There is no better way to assess their posterior and lateral extent nor properly monitor for tumor growth.”

- Paul T. Finger, MD


Iris Melanoma
New Insights into a Rare Eye Cancer

Dr. Finger organized members and Ophthalmic Oncology Task Force to perform an international, multicenter, internet-assisted study the clinical and pathologic characteristics of biopsy proven melanomas of the iris.

This study included 18 eye cancer specialists from 8 eye cancer centers in the USA, The Netherlands, Sweden, Finland, Canada and the United Kingdom. All patient information was privacy protected.

Data was gathered for 131 patients. Significant findings included: a mean age of 64, light irises in 91% and that the melanomas were typically located in the inferior “sun exposed” quadrants.

Kaplan-Meier statistical analysis found a 10.7% risk of metastatic melanoma at 5-years.

Multicenter data collection diminished selection bias and allowed for analysis of larger (more statistically significant) numbers of cases.

**CONCLUSIONS:**
Iris melanomas were typically:
- Brown
- In the bottom iris quadrants
- In patients with light irides
- More dangerous than expected

**REFERENCE:**

---

**Total Anterior Segment Plaque Radiation**

Multifocal iris and ring melanomas can be treated with ophthalmic plaque radiation therapy. Dr. Finger reported the first case of palladium-103 ophthalmic plaque used to cover the entire anterior segment of patient after multifocal biopsy showed that her entire iris was filled with melanoma.

Since that time, 3 more patients have been similarly treated allowing those patients to keep their eyes and vision. Though all are expected to develop cataract, no radiation retinopathy, optic neuropathy or neovascular glaucomas have been noted.

Dr Finger points out that “in contrast to enucleation (loss of the eye), this group of patients have clearly benefited from our technique.”

**REFERENCE:**
Dr. Finger has made iris biopsy safer for patients with iris tumors. In the past, this either involved using a sharp edged needle or opening the eye to grasp and snip a sample for pathology.

In 2005, Finger and colleagues published their initial experience using a 25-gauge aspiration cutter, inserted into the anterior segment through clear cornea (under viscoelastic). Termed, the “Finger Iridectomy Technique” this innovation decreased the risk associated with sharp needle biopsy and did not remove as much iris as iridectomy.

In 2011, Petousis and Milman published two related papers in The American Journal of Ophthalmology. The clinical paper reviewed Dr. Finger’s cases and found that small incision, aspiration cutter-assisted biopsy was safe and effective, with no cases of vision loss and 98% achieved a cytopathologic diagnosis. Similarly, Milman found that 41% contained enough material for cell-block preparations for more detailed pathologic study.

Dr. Finger says, “it has been my experience that my technique is a safer and more effective method to obtain iris tumor biopsy material compared to the fine needle technique.”

References

About Paul T. Finger, MD
Clinical Professor of Ophthalmology, Dr. Finger is a specialist in ocular tumors, orbital diseases and ophthalmic radiation therapy. He has developed new methods for the diagnosis and treatment of many ocular tumors, holds many patents and has written hundreds of scientific publications.

Dr. Finger is invited to lecture frequently at local, national and international meetings. He is founding Director of The New York Eye Cancer Center and The Ocular Tumor Services of The New York Eye and Ear Infirmary and NYU School of Medicine.

Dr. Finger is the Chair of the (AJCC) American Joint Committee on Cancer’s Ophthalmic Oncology Task Force and a member of the Committee on Cancer (COC) of the American College of Surgeons. Further, he consults for The American Brachytherapy Society (ABS) and the Association for Physicists in Medicine (AAPM).

For more information visit his web site: http://paultfingermd.com